Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/664—Amides of phosphorus acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/69—Boron compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/21—Interferons [IFN]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
  • A61N5/00—Radiation therapy
  • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/10—Spiro-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
  • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom

Definitions

• the present invention generally relates to cyclopamine analogs and pharmaceutical compositions thereof, and methods for preparing such analogs and compositions. These compounds and compositions are useful for the treatment of disorders mediated by the hedgehog pathway, such as cancer.
• Inhibition of the hedgehog pathway in certain cancers has been shown to result in inhibition of tumor growth.
• anti-hedgehog antibodies have been shown to antagonize the function of the hedgehog pathway and inhibit the growth of tumors.
• Small molecule inhibition of hedgehog pathway activity has also been shown to result in cell death in a number of cancer types.
• PCT publication WO 2006/026430 published 9 March 2006 and assigned to the same assignee as the present application, discloses a wide variety of cyclopamine analogs, focusing on those with unsaturation in the A or B ring.
• the surprisingly potent analogs contain completely saturated A and B rings.
• the present invention relates to analogs of steroidal alkaloids, such as cyclopamine, pharmaceutical compositions containing these compounds, and methods for preparing these compounds.
• the present invention relates to a compound represented by the following structure: or a pharmaceutically acceptable salt thereof; wherein R 1 is H, alkyl, -OR, amino, sulfonamido, sulfamido, -OC(O)R 5 , - N(R 5 )C(O)R 5 , or a sugar;
• R 3 is H, alkyl, alkenyl, or alkynyl
• R 4 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, -OR 5 , -C(O)R 5 , -CO 2 R 5 , -SO 2 R 5 , -C(O)N(R 5 )(R 5 ), -[C(R) 2 ] q -R 5 , -[(W)-N(R)C(0)] q R 5 , -[(W)-C(0)] q R 5 , -[(W)-C(0)0] q R 5 , -[(W)-0C(0)] q R 5 , -[(W)-SO 2 ] q R 5 , -[(W)-N(R 5 )SO 2 ] q R 5 , -[(W)-C(O)N(R 5
• each R 5 is independently H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl or -[C(R) 2 ] P -R 6 ; wherein p is 0-6; or any two occurrences of R 5 can be taken together to form a 4-8 membered optionally substituted ring which contains 0-3 heteroatoms selected from N, O, S, and P; each R 6 is independently hydroxyl, -N(R)COR, -N(R)C(O)OR, -N(R)SO 2 (R), -C(O)N(R) 2 , -OC(O)N(R)(R), -SO 2 N(R)(R), -N(R)(R), -COOR, -C(O)N(OH)(R), -OS(O) 2 OR, -C(O)N(OH)(
• R 1 is H, hydroxyl, alkoxyl, aryloxy, or amino.
• R 3 is H and/or R 4 is H, alkyl, hydroxyl, aralkyl, -[C(R) 2 ] q -R 5 , -[(W)-N(R)C(0)] q R 5 , -[(W)-N(R)SO 2 ] q R 5 , -[(W)-C(0)N(R)] q R 5 , -[(W)-0] q R 5 , -[(W)-C(0)] q R 5 , or -[(W)-C(0)0] q R 5 .
• R 1 is H or -OR
• R 2 is H or alkyl
• R 4 is H.
• R 2 is H or alkyl
• R 3 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, or aralkyl
• R 4 is H, alkyl, aralkyl, -[(W)-N(R)C(0)] q R 5 , -[(W)-N(R)SO 2 ] q R 5 , -[(W)-C(0)N(R)] q R 5 , -[(W)-0] q R 5 , -[(W)-C(0)] q R 5 , or -[(W)-C(0)0] q R 5 .
• R 1 is sulfonamide
• the present invention relates to a compound selected from the group consisting of:
• the compounds mentioned above are isolated.
• the present invention relates to an isolated compound selected from the group consisting of:
• the present invention relates to a compound represented by the following structure: or a pharmaceutically acceptable salt thereof; wherein R 1 is H, alkyl, -OR, amino, sulfonamido, sulfamido, -OC(O)R 5 , - N(R 5 )C(O)R 5 , or a sugar;
• R 3 is H, alkyl, alkenyl, or alkynyl
• R 4 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, -OR 5 , -C(O)R 5 , -CO 2 R 5 , -SO 2 R 5 , -C(O)N(R 5 )(R 5 ), -[C(R) 2 ] q -R 5 , -[(W)-N(R)C(0)] q R 5 , -[(W)-C(0)] q R 5 , -[(W)-C(0)0] q R 5 , -[(W)-0C(0)] q R 5 , -[(W)-SO 2 ] q R 5 , -[(W)-N(R 5 )SO 2 ] q R 5 , -[(W)-C(O)N(R 5
• X " is a halide; each R is, independently, H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl or -[C(R) 2 ] P -R 6 ; wherein p is 0-6; or any two occurrences of R 5 can be taken together to form a 4-8 membered optionally substituted ring which contains 0-3 heteroatoms selected from N, O, S, and P; each R 6 is, independently, hydroxyl, -N(R)COR, -N(R)C(O)OR, -N(R)SO 2 (R), -C(O)N(R) 2 , -OC(O)N(R)(R), -SO 2 N(R)(R), -N(R)(R), -COOR, -C(O)N(OH)(R), -OS(O) 2
• R 8 and R 9 are H;
• the compound is epimerically pure and/or isolated.
• R 4 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, -OR 5 , -[C(R) 2 ] q -R 5 , -[(W)-N(R)C(0)] q R 5 , -[(W)-C(0)] q R 5 , -[(W)-C(0)0] q R 5 , -[(W)-0C(0)] q R 5 , -[(W)-SO 2 ] q R 5 , -[(W)-N(R 5 )SO 2 ] q R 5 , -[(W)-C(O)N(R 5 )] q R 5 , -[(W)-0] q R
• the present invention relates to a compound selected from the group consisting of:
• the above compounds are epimerically pure and/or isolated.
• the present invention relates to an epimerically pure compound selected from the group consisting of:
• Another aspect of the present invention relates to a pharmaceutical composition including any of the aforementioned compounds, and a pharmaceutically acceptable excipient.
• the present invention relates to a process for preparing cyclopropyl derivatives of cyclopamine and related analogs having the formula 136:
• Y is CR 7 R 8 ;
• R 1 is H, alkyl, amino, hydroxyl, carboxyl, carbamoyl, alkoxy, hydroxyl, sugar or a protected hydroxyl group;
• R ' 3 , R " 4 , a aniidu R K. 5 i iss,, i unidueeppeeniidueeniitLliyy,, H n,, a alik ⁇ yyli,, a alik ⁇ eeniiyyli,, a alik ⁇ y; nyl, aryl, cycloalk kyyll,, hheetteerrooccyyccllooaallkkyyll,, aarralkyl, heteroaryl, or heteroaralkyl; or R 3 and R 4 or R 4 and R 31 taken together form a bond; R is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl,
• the process includes the steps of contacting a compound of formula 136a with a haloalkylzinc phosphate cyclopropanating agent to yield a compound of formula 136:
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 are as defined in compound 136.
• the present invention provides methods for preparing a compound of formula 137:
• Y is CR 7 R 8 ;
• R 1 is H, alkyl, amino, hydroxyl, carboxyl, carbamoyl, alkoxy, hydroxyl, sugar or a protected hydroxyl group;
• R is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, -OR 9 , -C(O)R 9 , -CO 2 R 9 , -SO 2 R 9 , -C(O)N(R 9 )(R 9 ), -[C(R 9 ) 2 ] q R 9 , -[(W)-N(R 9 )C(O)] q R 9 , -[(W)-C(0)] q R 9 , -[(W)-C(0)0] q R 9 , -[(W)-0C(0)] q R 9 , -[(W)-SO 2 ] q R 9 , -[(W)-N(R 9 )SO 2 ] q R 9 , -[(W)-C(O)N(
• R 1 , R 2 , R 3 , R 4 , R , R and Y are as defined in compound 137; and then contacting the compound of formula 137b with an acid to give a compound of formula 137.
• R 7 and R 8 can both be H; in other embodiments R 1 can be a protected hydroxyl; and/or R 6 is a nitrogen protecting group.
• the haloalkylzinc phosphate cyclopropanating agent is formed by combining a phosphoric acid of formula 141a, a dialkylzinc, and a dihaloalkylane of formula 141b:
• m is, independently for each occurrence, 0, 1, 2, 3, or 4; n is, independently for each occurrence, 0,1, or 2; and each of R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 18 is, independently, alkyl, aryl, aralkyl, or halide.
• the present invention relates to a process for preparing a compound of formula 142:
• the process includes the steps of contacting a compound of formula 142a with a cyclopropanating agent to form a compound formula 142b;
• Y is CR R ; R is a protected hydroxyl group;
• R 2 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; each of R 3 , R 4 , and R 5 is, independently, H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; or
• R 6 is a nitrogen protecting group;
• each of R 7 and R 8 is, independently, H, alkyl, alkenyl, aryl, nitrile, amido, halide, or ester;
• each R 9 is, independently, H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl.
• R and R can both be H; in other embodiments the protected hydroxyl group can be an ester or a carbonate; the nitrogen protecting can be a
• R carbamate or an amide R and R can both be H and the nitrogen protecting can be a carbamate or an amide; R 2 and R 3 can be H and R 4 and R taken together can form a bond; and/or the cyclopropanating agent is generated from a dihaloalkane and a metal species (e.g., dialkyl zinc or a zinc copper couple).
• a metal species e.g., dialkyl zinc or a zinc copper couple
• the cyclopropanating agent is generated from a dihaloalkane species and a dialkyl zinc species, and a phosphoric acid species or a salt thereof.
• the phosphoric acid species can have a structure of formula 151:
• each of R 10 and R 11 is independently alkyl, alkenyl, aralkyl, aryl, heteroaryl, heteroaralkyl; or R 10 and R 11 taken together have the formula 151a, 151b, or 151c;
• n independently for each occurrence is 0,1, or 2; each of R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 18 is, independently, alkyl, aryl, aralkyl, or halide.
• the acid is a Bronsted acid (e.g., acetic acid, trifluoromethanesulfonic acid, phosphoric acid, methanesulfonic acid or HCl).
• the acid is a Lewis acid (e.g., BF 3 , zinc chloride, zinc methanesulfonate, or a zinc salt).
• the present invention also relates to a process for preparing a compound of formula 156:
• the process includes the steps of: contacting a compound of formula 156a with a cyclopropanating agent to form a compound formula 156b;
• R 1 is an oxygen protecting group selected from the group consisting of formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, pivaloate, benzoate, alkyl carbonate, alkenyl carbonate, aryl carbonates, aralkyl carbonate, 2,2,2-trichloroethyl carbonate, alkoxymethyl ether, aralkoxymethyl ether, alkylthiomethl ether, aralkylthio ether, arylthio ether, trialkylsilyl ether, alkylarylsilyl ether, benzyl ether, arylmethyl ether, allyl ether; and R 2 is a nitrogen protecting group selected from the group consisting of formyl, chloroacetyl, trichloroacetyl, trifluoroacetyl, phenyl acetyl, benzoyl
• n independently for each occurrence is 0,1, or 2; each of R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 18 is, independently, alkyl, aryl, aralkyl, or halide.
• the oxygen protecting group can be, in some embodiments, selected from alkyl carbonates, aralkyl carbonates (e.g., benzylcarbonate), benzoates, pivaloate, or formate.
• the nitrogen protecting group can be selected from benzoyl, trichloroacetyl, trifluoroacetyl, formyl, alkyl carbamates, aralkyl carbamates (e.g., benzylcarbamate), aryl carbamates, diarylphosphinamides, dialkylphosphinamidates, or diarylphosphinamidates.
• each expression e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
• acylamino refers to a moiety that may be represented by the general formula:
• R50 wherein R50 and R54 independently represent a hydrogen, an alkyl, an alkenyl or -(CH 2 ) m -R61, where R61 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.
• alkenyl and alkynyl refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
• alkoxyl refers to an alkyl group, as defined above, having an oxygen radical attached thereto.
• Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
• alkyl refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
• a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), 20 or fewer.
• certain cycloalkyls have from 3-10 carbon atoms in their ring structure, and others have 5, 6 or 7 carbons in the ring structure.
• alkylthio refers to an alkyl group, as defined above, having a sulfur radical attached thereto.
• the "alkylthio" moiety is represented by one of -S-alkyl, -S-alkenyl, -S-alkynyl, and -S-(CH 2 ) m -R61, wherein m and R61 are defined above.
• Representative alkylthio groups include methylthio, ethyl thio, and the like.
• amino is art recognized as an amino-substituted carbonyl and includes a moiety that may be represented by the general formula:
• R50 and R51 each independently represent a hydrogen, an alkyl, an alkenyl, -(CH 2 ) m -R61, R61 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8, or R50 and R51, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure. Certain embodiments of the amide in the present invention will not include imides which may be unstable.
• amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas:
• R50 and R51 each independently represent a hydrogen, an alkyl, an alkenyl, or -(CH 2 ) m -R61, where R61 is defined as above.
• alkylamine includes an amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto, i.e., at least one of R50 and R51 is an alkyl group.
• aralkyl refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
• aryl as used herein includes 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, anthracene, naphthalene, pyrene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
• aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles" or “heteroaromatics.”
• the aromatic ring may be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, -CF3, -CN, or the like.
• aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
• Random acid refers to any substance that can act as a hydrogen ion (proton) donor.
• carboxyl is defined to include esters, thiocarboxyl, aldehydes, ketones and the like and thus includes such moieties as may be represented by the general formulas:
• X50 is a bond or represents an oxygen or a sulfur
• each of R55 and R56 represents independently a hydrogen, an alkyl, an alkenyl, -(CH 2 ) m -R61, where m and R61 are defined above.
• dirtyical refers to any of a series of divalent groups from alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, and heteroaralkyl
• alkyl heteroaralkyl diradical.
• Typical examples include alkylenes of general structure (CH 2 ) ⁇ where X is 1-6, and corresponding alkenylene and alkynylene linkers having 2-6 carbon atoms and one or more double or triple bonds; cycloalkylene groups having 3-8 ring members; and aralkyl groups wherein one open valence is on the aryl ring and one is
• haloalkyl refers to an alkyl group where anywhere from 1 to all hydgrogens have been replaced with a halide.
• a "perhaloalkyl” is where all of the hydrogens have been replaced with a halide.
• heteroatom as used herein means an atom of any element other than carbon or hydrogen.
• heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium.
• heterocyclyl or “heterocyclic group” refer to 3- to 10- membered ring structures, in some instances from 3- to 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can also be polycycles.
• Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, o
• the heterocyclic ring may be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF3, -CN, or the like.
• substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl,
• isolated in connection with a compound of the present invention means the compound is not in a cell or organism and the compound is separated from some or all of the components that typically accompany it in nature.
• Lower alkyl as used herein means an alkyl group, as defined above, but having from one to ten carbons, in some embodiments from one to six carbon atoms in its backbone structure. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths. Certain alkyl groups are lower alkyls. In some embodiments, a substituent designated herein as alkyl is a lower alkyl.
• nitro means -NO2; the term “halogen” designates -F, -Cl, -Br or -I; the term “sulfhydryl” means -SH; the term “hydroxyl” means -OH; and the term “sulfonyl” means -SO2-.
• polycyclyl or “polycyclic group” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings.
• Each of the rings of the polycycle may be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF3, -CN, or the like.
• substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl
• epimerically pure in connection with a compound of the present invention means that the compound is substantially free of stereoisomers of the compound wherein the configuration of the stereogenic center that R 3 is bonded to is inverted.
• an epimerically pure compound represented by the following formula:
• R 1 , R 2 , R 3 , R 4 , R 7 , R 7 , R 8 , and R 9 are as defined below, is substantially free of compounds represented by the following formula:
• R 1 , R 2 , R 3 , R 4 , R 7 , R 7 , R 8 , and R 9 are as defined below.
• Epimerically pure compounds contain less than about 20 % by mass, less than about 15% by mass, less than about 10% by mass, less than about 5% by mass, or less than about 3% by mass of stereoisomeric compounds wherein the configuration of the stereogenic center that R 3 is bonded to is inverted relative to the compound.
• protecting group means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations.
• protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively.
• the field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P.G.M. Protective Groups in Organic Synthesis, 2 nd ed.; Wiley: New York, 1991).
• the functional group being protected and the protecting group are together referred to as one moiety.
• the fragment shown below is sometimes referred to as a benzyl carbonate; i.e., the protected (underlined) O makes up part of the carbonate.
• saccharide refers to a natural or an unnatural monosaccharide, disaccharide or oligosaccharide comprising one or more pyranose or furanose rings.
• the sugar may be covalently bonded to the steroidal alkaloid of the present invention through an ether linkage or through an alkyl linkage.
• the saccharide moiety may be covalently bonded to a steroidal alkaloid of the present invention at an anomeric center of a saccharide ring.
• Sugars may include, but are not limited to ribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, glucose, and trehalose.
• R50 O O wherein R50 and R56 are as defined above.
• triflyl refers to trifluoromethanesulfonyl, p-toluenesulfonyl, methanesulfonyl, and nonafluorobutanesulfonyl groups, respectively.
• triflate refers to trifluoromethanesulfonate ester, p-toluenesulfonate ester, methanesulfonate ester, and nonafluorobutanesulfonate ester functional groups and molecules that contain the groups, respectively.
• substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
• Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms.
• the present invention contemplates all such compounds, including CM- and trans -isomers, R- and 5-enantiomers, diastereomers, (D)- isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
• Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
• certain embodiments of the present compounds may contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable acids.
• pharmaceutically-acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed during subsequent purification.
• Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
• sulfate bisulfate
• phosphate nitrate
• acetate valerate
• oleate palmitate
• stearate laurate
• benzoate lactate
• phosphate tosylate
• citrate maleate
• fumarate succinate
• tartrate napthylate
• mesylate mesylate
• glucoheptonate lactobionate
• laurylsulphonate salts and the like See, for example, Berg
• the pharmaceutically acceptable salts of the compounds of the present invention include the conventional nontoxic salts or quaternary ammonium salts of the compounds, e.g., from non-toxic organic or inorganic acids.
• such conventional nontoxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.
• the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically- acceptable salts with pharmaceutically-acceptable bases.
• pharmaceutically- acceptable salts refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically- acceptable organic primary, secondary or tertiary amine.
• Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
• Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. (See, for example, Berge et al, supra)
• the ring expanded steroidal alkaloid derivatives described above can be prepared directly from naturally occurring steroidal alkaloids or synthetic analogs thereof.
• the steroidal alkaloid starting materials can be cyclopamine or jervine. These steroidal alkaloids can be purchased commercially or extracted from Veratrum Californicum.
• the process of the present invention comprises the steps of cyclopropanating suitable starting steroidal alkaloid derivatives followed by ring expansion rearrangement of the cyclopropyl derivatives. In some instances, it may be desirable to suitably protect or otherwise transform reactive functionalities present on the molecule prior to cyclopropanation.
• an alcohol present at R 1 and a secondary nitrogen present on the fused furano-piperidine ring can both be protected prior to cyclopropanation.
• protecting groups that are efficiently added and removed from the alkaloid, yield intermediates in the synthetic process with improved handling properties and which allow for the efficient purification of the synthetic intermediates formed may be preferred.
• oxygen protecting groups include, but are not limited to formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, pivaloate, benzoates, alkyl carbonate, alkenyl carbonate, aryl carbonates, aralkyl carbonate (e.g., benzyl carbonate), 2,2,2-trichloroethyl carbonate, alkoxymethyl ether, aralkoxymethyl ether, alkylthiomethl ether, aralkylthio ether, arylthio ether, trialkylsilyl ether, alkylarylsilyl ether, benzyl ether, arylmethyl ether, and allyl ether.
• formate acetate, chloroacetate, dichloroacetate, trichloroacetate, pivaloate
• benzoates alkyl carbonate, alkenyl carbonate, aryl carbonates, aralkyl carbonate (e.g., benzyl
• nitrogen protecting groups include, but are not limited to formyl, chloroacetyl, trichloroacetyl, trifluoroacetyl, phenyl acetyl, benzoyls, benzamides, alkyl carbamates, aralkyl carbamates (e.g., benzyl carbamates), aryl carbamates, allyl, aralkyl, alkoxymethyl, aralkoxymethyl, N-2-cyanoethyl, diary lphosphinamides, dialkylphosphinamidates, diarylphosphinamidates, and trialkylsilyl.
• cyclopropanating agents can be used to cyclopropanate the steroidal alkaloid.
• 1 -haloalkylmetal complexes and reactive species referred to as carbenoids are commonly used to cyclopropanate olefins.
• These reagents are typically made using a diiodoalkane or diazoalkane and a metal or organometalic species such as Et 2 Zn, JBu 3 Al, samarium, copper, rhodium, or palladium.
• Et 2 Zn and diiodomethane are used to generate the 1,1 -haloalkylmetal species.
• the reactivity and the ease of handling of the 1,1 -haloalkylzinc complexes can be modified by the addition of certain reagents, such as acids. It is believed that the addition of an acid to the 1,1 -haloalkylzinc species generates an alkyl zinc mixed salt.
• a biarylphosphoric acid is combined with diiodomethane and diethylzinc to generate a putative haloalkyl zinc phosphate cyclopropanating agent.
• a variety of phosphoric acids can be used to generate the putative haloalkylzinc phosphate.
• cyclopropanation methods such as those utilizing sulfur ylides to react with an olefin conjugated to a carbonyl to add a CH 2 or CH-alkyl or CH- aryl group, and metal-catalyzed decomposition of diazoalkyl and ⁇ -diazo-carbonyl compounds, such as diazomethane and ethyl diazoacetate, can also be used: these methods readily provide cyclopropanes having alkyl, aryl, alkoxycarbonyl (-COOR), or acyl substituents. Additional cyclopropanating agents are described in Masalov et al., Organic Letters (2004) Vol. 6, pp. 2365-8 and Hansen et al., Chem. Comm. (2006) 4838- 40.
• the cyclopropyl ring may be substituted or unsubstituted. In cases where the cyclopropyl ring is substituted, the groups attached to the methylene of the cyclopropane will be installed onto the D ring after rearrangement and ring expansion. [0073] The cyclopropanation reactions may be conducted in an aprotic solvent.
• Suitable solvents include ethers, such as diethyl ether, 1,2-dimethoxyethane, diglyme, t- butyl methyl ether, tetrahydrofuran and the like; halogenated solvents, such as chloroform, dichlorome thane, dichloroethane, and the like; aliphatic or aromatic hydrocarbon solvents, such as benzene, xylene, toluene, hexane, pentane and the like; esters and ketones, such as ethyl acetate, acetone, and 2-butanone; polar aprotic solvents, such as acetonitrile, dimethylsulfoxide, dimethylformamide, and the like; or combinations of two or more solvents.
• dichlorome thane is the solvent used for the cyclopropanation when a dialkyl zinc and diiodomethane is used.
• a solution containing the cyclopropanating agent is prepared by first adding a solution of a phosphoric acid to a solution of diethylzinc, followed by addition of diiodomethane to the reaction solution.
• the cyclopropanation substrate is then added to this solution.
• the cyclopropanation agent can be prepared in the presence of the cyclopropanation substrate by changing the order of addition of the reagents.
• the cyclopropanation reaction is conducted by first adding the phosphoric acid to a solution of dialkylzinc, followed by the addition of the cyclopropanation substrate, and finally the dihaloalkane is added.
• cyclopropanating agent is generated under controlled conditions and immediately reacts with the cyclopropanation substrate.
• the cyclopropanation methods described herein can also be used to cyclopropanate other polycyclic compounds, for example, those with steroidal backbones.
• the compound may be derivatized using a variety of functionalization reactions known in the art.
• Representative examples include palladium coupling reactions to alkenylhalides or aryl halides, oxidations, reductions, reactions with nucleophiles, reactions with electrophiles, pericyclic reactions, radical reactions, installation of protecting groups, removal of protecting groups, and the like.
• the cyclopropyl analogs undergo a rearrangement and ring expansion to afford steroidal alkaloid analogs in which the D ring has been expanded by one carbon.
• the cyclopropanation and ring expansion can take place in a two-step one reaction vessel process or in a two-step two reaction vessel process.
• the acid used to initiate the ring expansion rearrangement is added after completion of the cyclopropanation reaction.
• the zinc salts that are generated in the course of cyclopropanating the steroidal alkaloid can themselves act as Lewis acids to catalyze the ring expansion rearrangement.
• the reactivity of the zinc salts generated after the cyclopropanation can be modified by the addition of acids to generate more active Lewis acids.
• the methanesulfonic acid is added to the cyclopropanation reaction vessel after completion of the cyclopropanation.
• suitable acids include, but are not limited to zinc salts, boron compounds, magnesium salts, titanium salts, indium salts, aluminum salts, tin salts, lanthanum salts, trifluoromethanesulfonic acid, diaryloxyphosporic acids, acetic acid, and HCl.
• the Lewis acid used is a zinc salt or BF 3 .
• ring expanded analogs may be further functionalized using a variety of functionalization reactions known in the art.
• Representative examples include palladium coupling reactions to alkenylhalides or aryl halides, oxidations, reductions, reactions with nucleophiles, reactions with electrophiles, pericyclic reactions, radical reactions, installation of protecting groups, removal of protecting groups, and the like.
• Hedgehog signaling is essential in many stages of development, especially in formation of left-right symmetry. Loss or reduction of hedgehog signaling leads to multiple developmental deficits and malformations, one of the most striking of which is cyclopia.
• lung cancer (Watkins et al. (2003) Nature 422: 313-317), prostate cancer (Karhadkar et al (2004) Nature 431 : 707-12, Sheng et al. (2004) Molecular Cancer 3: 29-42, Fan et al. (2004) Endocrinology 145: 3961-70), breast cancer (Kubo et al. (2004) Cancer Research 64: 6071-74, Lewis et al. (2004) Journal of Mammary Gland Biology and Neoplasia 2: 165-181) and hepatocellular cancer (Sictician et al. (2005) ASCO conference, Mohini et al. (2005) AACR conference).
• small molecule inhibition of the hedgehog pathway has been shown to inhibit the growth of basal cell carcinoma (Williams, et al., 2003 PNAS 100: 4616-21), medulloblastoma (Berman et al., 2002 Science 297: 1559-61), pancreatic cancer (Berman et al., 2003 Nature 425: 846-51), gastrointestinal cancers (Berman et al., 2003 Nature 425: 846-51, published PCT application WO 05/013800), esophageal cancer (Berman et al., 2003 Nature 425: 846-51), lung cancer (Watkins et al., 2003. Nature 422: 313-7), and prostate cancer (Karhadkar et al., 2004. Nature 43J_: 707-12).
• the present invention provides pharmaceutically acceptable compositions which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
• the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, capsules, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for
• aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
• polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
• vegetable oils such as olive oil
• injectable organic esters such as ethyl oleate.
• Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
• compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, dispersing agents, lubricants, and/or antioxidants.
• adjuvants such as preservatives, wetting agents, emulsifying agents, dispersing agents, lubricants, and/or antioxidants.
• Prevention of the action of microorganisms upon the compounds of the present invention may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like.
• isotonic agents such as sugars, sodium chloride, and the like into the compositions.
• prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
• Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
• the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
• the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, about 0.1 to 99%, or about 10 to 50%, or about 10 to 40%, or about 10 to 30, or about 10 to 20%, or about 10 to 15% of active ingredient in combination with a pharmaceutically acceptable carrier.
• compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
• the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
• a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
• oral, intravenous and subcutaneous doses of the compounds of the present invention for a patient when used for the indicated effects, will range from about 0.0001 to about 100 mg, or about 0.001 to about 100 mg, or about 0.01 to about 100 mg, or about 0.1 to about 100 mg per, or about 1 to about 50 mg per kilogram of body weight per day.
• the subject receiving this treatment is any animal in need, including primates, in particular humans, and other mammals such as equines, cattle, swine and sheep; and poultry and pets in general.
• Recrystallized cyclopamine 2 (14.1 g, 34.0 mmol, 1 eq) is dissolved in anhydrous DCM (70 mL) and anhydrous MeOH (29 mL). The clear solution is cooled, and triethylamine (10.4 g, 102.7 mmol, 3 eq) followed by benzyl chloroformate (6.20 g, 36.3 mmol, 1.1 eq) is added. After the addition is complete, the solution is stirred in the ice bath for 30 mm. Three portions of benzyl chloroformate (3 X 0.35 g, 3.46 mmol, 0.03 eq) are added over the 3 h.
• the reaction is slowly quenched with water (71 mL), while maintaining the temperature below 20 0 C.
• the mixture is stirred for 15 mm before the layers are settled and separated.
• the organic layer is dried over sodium sulfate and filtered.
• the combined filtrate is buffered with anhydrous pyridine (30 mL), concentrated, and solvent exchanged with additional anhydrous pyridine (43 mL) and concentrated.
• Bis(2,6-dimethyphenyl)phosphate (10.65 g, 34.8 mmol, 3.1 eq) is dried by concentration from anhydrous DCM (42 mL) and held under a nitrogen atmosphere. The phosphate is then redissolved in anhydrous DCM (110 mL). In a separate flask, a solution of neat diethylzinc (4.17 g, 33.8 mmol, 3.0 eq) in anhydrous DCM (35 mL) is prepared and cooled to -25 0 C. The phosphate solution is slowly transferred to the vessel containing the diethylzinc solution over 1 h, maintaining the temperature at or below -10 0 C.
• the solution is filtered under nitrogen, and the filtrate is washed with a 2 % (wt/wt) aqueous solution of ethylenediamine (125 mL) then water (130 mL), and then dried over sodium sulfate.
• the drying agent is removed by filtration and the filtrate is concentrated to dryness under vacuum.
• the solids that remained are chased with toluene (2 x 55 mL) on the rotary evaporator and the resulting material used without further purification in the next step
• a round bottom flask is sequentially charged with the homo-allylic alcohol (7.50 g, 17.6 mmol, 1 eq), aluminum tri-fe?t-butoxide (6.10 g, 24.8 mmol, 1.4 eq), anhydrous toluene ( 115 mL), and 2-butanone (90 g, 1.24 mol, 7 eq).
• the suspension is heated under a nitrogen atmosphere to 75 0 C for 16 h.
• the reaction temperature is then allowed to cool to 49 0 C.
• Aqueous 20 % (w/w) potassium sodium tartrate solution (226 g) is added to the stirred suspension.
• the suspension is stirred at rt for 3.5 h.
• the layers are separated.
• Cyclopamine 2 (5.02 g, 12.2 mmol, 1.0 eq) is dissolved in anhydrous pyridine (25 mL).
• DMAP 300 mg, 2.44 mmol, 0.2 eq.
• triethyl amine 5.5 mL, 39.1 mmol, 3.2 eq
• BtO-Cbz 10.5 g, 39.1 mmol, 3.2 eq
• the mixture is cooled to rt, treated with 30 mL water, heated to get a homogeneous solution and allowed to cool to room temp.
• a round bottom flask is sequentially charged with the homo-allylic alcohol 8 (7.50 g, 17.6 mmol, 1 eq), aluminum tri-fe?t-butoxide (6.10 g, 24.8 mmol, 1.4 eq), anhydrous toluene (115 mL), and 2-butanone (90 g, 1.24 mol, 7 eq).
• the suspension is heated under a nitrogen atmosphere to 75 0 C for 16 h.
• the reaction temperature is then allowed to cool to 49 0 C.
• Aqueous 20 % (w/w) potassium sodium tartrate solution (226 g) is added to the stirred suspension.
• the suspension is stirred at rt for 3.5 h.
• the layers are separated.
• ketone 6 85 mg, 0.199 mmol, 1 equiv. was charged and triethyleneglycol (2 mL) was added followed by hydrazine monohydrate (500 mg, 10 mmol, 50 equiv.) and potassium carbonate (138 mg, 1 mmol, 5 equiv.).
• the tube was sealed and the reaction was heated at 150 0 C for 16 h.
• the reaction was cooled to rt and water was added.
• the residue was extracted with chloroform (3X).
• the combined organic layers are washed with water, dried over Na 2 SO 4 , and concentrated to dryness.
• the colorless oil was purified using silica gel flash chromatography (DCM/MeOH 96:4).
• the reaction was cooled to rt and water was added.
• the residue was extracted with MTBE (3X).
• the organic layers were combined washed with brine, dried over Na 2 SO 4 , filtered, and concentrated to dryness.
• the white foam was purified using silica gel flash chromatography (DCM/MeOH 99:1) to give 206 mg of the N-isopropyl derivative as a white foam.
• the crude was purified using silica gel flash chromatography (hexane/EtOAc (9:1 to 4: 1)) to give the N-O derivative product (60 mg, 0.11 mmol) as a white foam.
• This foam was dissolved in 2 mL of MeOH followed by 2N aqueous KOH (0.4 mL). The reaction mixture was stirred for Ih. Most of the MeOH was evaporated under a stream of nitrogen and IN HCl (500 ⁇ L) was added. The material was extracted with DCM (3X). The combined organic layers were washed with water, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
• Recrystallized cyclopamine (2.07 g) is charged to an appropriately sized reaction vessel and placed under an inert atmosphere.
• EtOAc (7.6 g), triethylamine (1.53 g), and DMAP (307 mg) are added sequentially.
• the suspension is warmed to 4O 0 C.
• Cbz-OBt is added in three portions over 90 minutes, keeping the internal temperature below 45 0 C.
• the reaction mixture is stirred at 4O 0 C for 90 minutes.
• the temperature is maintained while methanol (26.4 g) is slowly added to the reaction mixture.
• the resulting suspension is cooled to room temperature and stirred for at least 15 hours.
• the crude product is collected by filtration and rinsed with methanol (5 g).
• the white solid is dried under vacuum to a constant weight and recrystallized from heptane (30.3 g) and toluene (3.2 g) to afford Compound 24a (3.0 g).
• Johnson Matthey Pd/C catalyst A-305038-5 (890 mg) is charged to an appropriately sized reaction vessel, followed by 24b (2.24 g).
• the reaction vessel is purged with N 2 and toluene (21.8 g) and 2-propanol (6.7 g) are added sequentially.
• the system is degassed and placed under a nitrogen atmosphere, and the process is repeated with hydrogen.
• the system is stirred vigorously and the hydrogen blanket is maintained at one atmosphere for 4-5 hours.
• the reaction is monitor by either TLC or HPLC. If incomplete, the reaction is inerted, additional catalyst (145 mg) is charged, and the hydrogen atmosphere is returned for another hour. Ethylenediamine (12.9 mg) is charged and the mixture was stirred for 15 minutes.
• the catalyst is removed by filtration with a toluene:IPA (3:1) rinse.
• the filtrate and rinses are concentrated and solvent exchanged to toluene.
• the product is crystallized from toluene (19.0 g) and heptane (18.0 g) to afford 24c as a white crystalline solid (1.34 g, 98% yield).
• 24c (644 mg) is charged to an appropriately sized reaction vessel followed by aluminum t-butoxide (525 mg), toluene (8.34 g, 15 vol), and 2-butanone (7.83 g, 15 vol).
• the contents of the flask are degassed with evacuation/nitrogen purge cycles to remove oxygen and the reaction mixture is heated at 75°C with vigorous stirring for 16-18 hours.
• the reaction is quenched by the addition of aqueous Rochelle's salt (2.6 g in 10.3 g water) and the mixture vigorously stirred for one hour at 45 0 C.
• the aqueous and organic layers are separated.
• the aqueous layer is back extracted with a mixture of toluene (2.9 g) and EtOAc (2.9 g).
• the enone 24d (459 mg) and Johnson-Matthey 5% palladium on carbon (A503023-5, 101 mg) are charged to an appropriately sized multi neck reaction vessel.
• the vessel is purged with nitrogen and 3-picoline (2.2 g) is charged as the solvent. Stirring is started and the vessel is first degassed using nitrogen and then stirred under hydrogen at atmospheric pressure for 8 hours.
• the catalyst is removed by filtration through 0.2 micron media, rinsing with ACN (1.4 ml). The filtrate and rinse are combined in a clean reaction vessel equipped with mechanical stirring, an internal temperature probe, and a nitrogen atmosphere.
• citric acid (3.7 g) in water (9.2 ml) is charged to the reaction vessel at or below 3O 0 C, and IPI-335589 is allowed to slowly crystallize from solution as the citrate salt at 20 and then O 0 C.
• the crystalline product is recovered by suction filtration and washed with water (3.7 ml). After drying, the citrate salt, 24e, is isolated as a hydrate (3-5 wt% water) in 89.5% yield (622 mg) with a ⁇ : ⁇ ratio approaching 90:1.
• the reaction is quenched at low temperature with MeOH (0.33 g), then 3M NaOH (2.4 g) at -20 0 C and 15% hydrogen peroxide in water (1.04 g) at or below 5°C, then stirring overnight at ambient temperatures.
• the layers are split and the organic layer is washed sequentially with IM aqueous NaOH (2 ml), 0.5 M aqueous Na 2 SO 3 (2 ml), and water (2 ml) adjusted to a pH of 3 with HCl.
• the organic layer is dried over sodium sulfate (0.82 g), filtered and concentrated.
• the product 24g (0.457 g) is re-concentrated from DCM (0.9 g) and used in the next reaction.
• the layers are separated and the organic layer is washed with 2.5 wt% sodium bicarbonate (13.8 g) and then water (10.9 g). The organic layer is dried over of sodium sulfate (4 g), filtered, and concentrated.
• the product solution is solvent exchanged via charge and concentration to t-butyl methyl ether (10.9 ml) and then l,3-dimethyl-3,4,5,6-tetrahydro- 2(lH)-pyrimidinone (DMPU, 4.7 ml). The DMPU solution is used directly in the next reaction.
• 24j (1.09 g) is dissolved and transferred to an appropriately sized reaction vessel with anhydrous DCM (15.8 g) and placed under a nitrogen atmosphere. The solution is cooled to 0 0 C. N,N-diisopropylethylamine (357 mg) and neat methanesulfonyl chloride (0.165 ml) are charged sequentially while maintaining temperature between below 5 0 C. The reaction is monitored by HPLC. Incomplete reactions are driven to completion with additional methanesulfonyl chloride. The reaction is quenched with 0.4 M aqueous sodium bicarbonate (11.4 g) and warmed to ambient temperature. The layers are separated and the aqueous phase is back extracted with DCM (5.8 g). The combined organic layers are dried over magnesium sulfate (0.55 g), filtered and concentrated. The product 24k is dissolved and striped from 2- propanol (4.0 g) to remove residual DCM and used directly in the next reaction.
• the reaction is stirred under 1 atm of hydrogen for another 15 hours at ambient temperature.
• the reaction is monitored by HPLC. Incomplete reactions are treated with additional catalyst and hydrogen.
• the reaction is filtered, treated with steam activated carbon (200 mg), and filtered again.
• the solution is dried by partial concentration transferred to a reaction vessel and diluted with anhydrous 2-propanol to 0.09 M based on the theoretical yield.
• a 1.25 M HCl solution in 2- propanol (1.64 g) is charged over 20 minutes.
• the hydrochloride salt crystallizes slowly with gentle stirring and is isolated by filtration.
• the crystals are washed with 2-propanol (2.5 g) and vacuum dried to afford Compound 42 (916 mg, 80% yield) as a 1:1 IPA solvate.
• Step B The mixture was diluted with CH 2 CI 2 (30 mL) and washed with three portions (30 mL each) of water. The organic layer was dried over Na 2 SO 4 , filtered, and evaporated to dryness. The desired white solid 51 was taken to the next step without purification.
• the ketone 57 was azeotroped a couple times with CH 2 CI 2 and dried under vacuum for 1 h. Under nitrogen, the ketone 2 (693 mg, 1.27 mmol, 1 equiv.) was dissolved in anhydrous THF (20 mL) and the solution was cooled to -78C. A I M solution of K-selectride in THF (1.9 mL, 1.9 mmol, 1.5 equiv.) was added dropwise. After 1 h, the reaction was complete by TLC. The reaction was quenched by addition of 2.6 mL of 5 N NaOH followed by slow addition of 2.6 mL of 30% wt H 2 O 2 .
• Example 28 Inhibition of the Hedgehog pathway in cell culture
• Hedgehog pathway specific cancer cell killing effects may be ascertained using the following assay.
• C3H10T1/2 cells differentiate into osteoblasts when contacted with the sonic hedgehog peptide (Shh-N). Upon differentiation; these osteoblasts produce high levels of alkaline phosphatase (AP) which can be measured in an enzymatic assay (Nakamura et al., 1997 BBRC 237: 465).
• AP alkaline phosphatase
• Compounds that block the differentiation of C3H10T1/2 into osteoblasts can therefore be identified by a reduction in AP production (van der Horst et al., 2003 Bone 33: 899).
• the assay details are described below.
• the results approximate (EC 50 for inhibition) of the differentiation assay is shown below in Table 1.
• Mouse embryonic mesoderm fibroblasts C3H10T1/2 cells obtained from ATCC were cultured in Basal MEM Media (Gibco/Invitrogen) supplemented with 10% heat inactivated FBS (Hyclone), 50 units/ml penicillin and 50ug/ml streptomycin (Gibco/Invitrogen) at 37C with 5% CO2 in air atmosphere.
• C3H10T1/2 cells were plated in 96 wells with a density of 8xlO 3 cells/well. Cells were grown to confluence (72hrs). After sonic Hedgehog (250ng/ml), and/or compound treatment, the cells were lysed in 110 ⁇ L of lysis buffer (50 mM Tris pH 7.4, 0.1% TritonXlOO), plates were sonicated and lysates spun through 0.2 ⁇ m PVDF plates (Corning). 40 ⁇ L of lysates was assayed for AP activity in alkaline buffer solution (Sigma) containing lmg/ml p-Nitrophenyl Phosphate.
• lysis buffer 50 mM Tris pH 7.4, 0.1% TritonXlOO
• the activity of Compound 42 was also evaluated in a transgenic mouse model of medulloblastoma. Mice that are heterozygous for loss of function mutations in the tumor suppressors Patchedl (Ptchl) and Hypermethylated in Cancer (Hicl) develop spontaneous medulloblastoma. Similar to human medulloblastoma, these tumors demonstrate complete promoter hypermethylation of the remaining Hicl allele, as well as loss of expression of the wild type Ptchl allele. When passaged as subcutaneous allografts, these tumors grow aggressively and are Hedgehog pathway-dependent. This model was employed to evaluate the efficacy of orally administered Compound, and to correlate activity with drug exposure in plasma and tumors. Oral administration (PO) of a single dose of Compound 42 led to dose-dependent down-regulation of the HH pathway in subcutaneously implanted tumors, as measured by decreased GIi-I mRNA expression 8 hours post dose administration.
• Ptchl tumor suppressors Patchedl
• LX22 cells were implanted subcutaneously into the flank of the right leg.
• LX22 is primary xenograft model of SCLC derived from chemo -naive patients, which has been maintained by mouse to mouse passaging. This tumor responds to etoposide/carboplatin chemotherapy in way that closely resembles a clinical setting. LX22 regresses during chemotherapy treatment, goes through a period of remission, and then begins to recur.
• Compound single agent activity and its ability to modulate the chemoresistant recurrence was tested.
• mice were randomized into three dosing groups to receive Vehicle (30% HBPCD), Compound, or the chemotherapy combination of etoposide and carboplatin (E/P).
• Compound 42 was administered at a dose of 40mg/kg/day, and after 16 consecutive doses there was no measurable difference between the treated and vehicle groups.
• Etoposide was administered i.v at 12mg/kg on days 34, 35, 36, and 48, while Carboplatin was administered i.v. at 60mg/kg on days 34, 41, and 48, post tumor implant.
• the E/P treated mice were further randomized to receive either Vehicle (30%HPBCD) or Compound follow up treatment.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Dermatology (AREA)
• Pathology (AREA)
• Radiology & Medical Imaging (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Steroid Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (19)

Applications Claiming Priority (4)

Publications (2)

Family

ID=39589207

Family Applications (2)

Family Applications After (1)

Country Status (25)

Cited By (15)

Families Citing this family (57)

Family Cites Families (145)

• 2007
  • 2007-12-24 TW TW096149773A patent/TWI433674B/zh active
  • 2007-12-27 EP EP11189894A patent/EP2443926A3/en not_active Withdrawn
  • 2007-12-27 US US11/965,675 patent/US8017648B2/en active Active
  • 2007-12-27 JP JP2009544277A patent/JP5542448B2/ja active Active
  • 2007-12-27 BR BRPI0720972A patent/BRPI0720972B8/pt active IP Right Grant
  • 2007-12-27 PL PL07870001T patent/PL2096917T3/pl unknown
  • 2007-12-27 JO JO2007564A patent/JO2947B1/en active
  • 2007-12-27 AU AU2007339782A patent/AU2007339782B2/en active Active
  • 2007-12-27 CN CN200780051114.7A patent/CN101631463B/zh active Active
  • 2007-12-27 NO NO20190059A patent/NO347310B1/no unknown
  • 2007-12-27 PT PT78700010T patent/PT2096917E/pt unknown
  • 2007-12-27 RU RU2009128997/04A patent/RU2486194C2/ru active
  • 2007-12-27 DK DK07870001.0T patent/DK2096917T3/da active
  • 2007-12-27 AU AU2007339786A patent/AU2007339786B2/en active Active
  • 2007-12-27 ES ES07870001.0T patent/ES2488466T3/es active Active
  • 2007-12-27 MX MX2012007856A patent/MX342683B/es unknown
  • 2007-12-27 JP JP2009544276A patent/JP5412292B2/ja active Active
  • 2007-12-27 CA CA2673995A patent/CA2673995C/en active Active
  • 2007-12-27 SG SG2011096666A patent/SG177929A1/en unknown
  • 2007-12-27 CN CN200780051112.8A patent/CN101677551B/zh active Active
  • 2007-12-27 WO PCT/US2007/088990 patent/WO2008083248A2/en not_active Ceased
  • 2007-12-27 ES ES07870006.9T patent/ES2612746T3/es active Active
  • 2007-12-27 MX MX2009007077A patent/MX2009007077A/es active IP Right Grant
  • 2007-12-27 US US11/965,688 patent/US7812164B2/en active Active
  • 2007-12-27 CA CA2674302A patent/CA2674302C/en active Active
  • 2007-12-27 KR KR1020097015914A patent/KR101482693B1/ko active Active
  • 2007-12-27 KR KR1020097015913A patent/KR101489394B1/ko active Active
  • 2007-12-27 MX MX2009007075A patent/MX2009007075A/es active IP Right Grant
  • 2007-12-27 EP EP07870001.0A patent/EP2096917B1/en active Active
  • 2007-12-27 NZ NZ577916A patent/NZ577916A/xx unknown
  • 2007-12-27 BR BRPI0720993A patent/BRPI0720993B8/pt active IP Right Grant
  • 2007-12-27 RU RU2009129000/15A patent/RU2492859C2/ru active
  • 2007-12-27 EP EP11165825.8A patent/EP2368551B1/en active Active
  • 2007-12-27 NZ NZ578053A patent/NZ578053A/xx unknown
  • 2007-12-27 SG SG2011096674A patent/SG177930A1/en unknown
  • 2007-12-27 WO PCT/US2007/088995 patent/WO2008083252A2/en not_active Ceased
  • 2007-12-27 EP EP07870006.9A patent/EP2101580B1/en active Active
  • 2007-12-28 CL CL200703854A patent/CL2007003854A1/es unknown
  • 2007-12-28 AR ARP070105973A patent/AR081107A1/es active IP Right Grant
• 2008
  • 2008-01-02 PE PE2008000074A patent/PE20090042A1/es active IP Right Grant
  • 2008-08-27 US US12/199,722 patent/US8669365B2/en active Active
  • 2008-08-27 US US12/199,689 patent/US8785635B2/en active Active
• 2009
  • 2009-06-25 ZA ZA2009/04446A patent/ZA200904446B/en unknown
  • 2009-06-25 ZA ZA2009/04445A patent/ZA200904445B/en unknown
  • 2009-06-25 IL IL199554A patent/IL199554B/en active IP Right Grant
  • 2009-07-20 NO NO20092710A patent/NO343748B1/no unknown
  • 2009-07-20 NO NO20092711A patent/NO344315B1/no not_active IP Right Cessation
• 2011
  • 2011-04-20 US US13/090,694 patent/US20110230509A1/en not_active Abandoned
  • 2011-07-27 US US13/191,545 patent/US8227509B2/en active Active
• 2012
  • 2012-05-18 US US13/475,510 patent/US20130108583A1/en not_active Abandoned
  • 2012-05-18 US US13/475,352 patent/US8895576B2/en active Active
• 2013
  • 2013-10-15 US US14/054,350 patent/US9145422B2/en active Active
• 2014
  • 2014-03-10 US US14/203,297 patent/US9492435B2/en active Active
• 2015
  • 2015-08-31 US US14/841,001 patent/US9669011B2/en active Active
• 2016
  • 2016-10-10 US US15/289,887 patent/US9951083B2/en active Active
• 2017
  • 2017-05-02 US US15/585,038 patent/US10045970B2/en active Active
• 2018
  • 2018-03-27 US US15/936,919 patent/US10406139B2/en active Active
  • 2018-07-27 US US16/047,008 patent/US10314827B2/en active Active
• 2019
  • 2019-04-26 US US16/396,565 patent/US10821102B2/en active Active
  • 2019-07-24 US US16/521,447 patent/US11007181B2/en active Active
• 2020
  • 2020-09-28 US US17/035,611 patent/US11602527B2/en active Active

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events